Sugi Predict

Sugi Predict / Compounds / SCHEMBL1094296

SCHEMBL1094296

SCHEMBL1094296

CC(C)(C)OC(=O)NNC1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KDM4D Q6B0I6 6/20 0.43
▸ SLC6A9 P48067 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ KDM1A O60341 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ CCR5 P51681 1/20 0.42
▸ KCNA3 P22001 1/20 0.42
▸ CNR1 P21554 1/20 0.41
▸ CNR2 P34972 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ CTSL P07711 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2793927 0.91 KMT2A (0.49) KMT2AMEN1KDM4DL3MBTL1KDM1A
SCHEMBL18634553 0.82 KDM4D (0.53) KMT2AKDM4DL3MBTL1CCR5CNR1
SCHEMBL18634336 0.82 KDM4D (0.53) KMT2AKDM4DL3MBTL1CCR5CNR1
SCHEMBL22151315 0.82 SLC6A9 (0.44) KMT2AMEN1SLC6A9CCR5CNR1
SCHEMBL15607989 0.81 CTSK (0.45) KMT2AMEN1SLC6A9ACHECTSL
SCHEMBL1744817 0.80 NPSR1 (0.49) KMT2AMEN1SLC6A9L3MBTL1MAOB
SCHEMBL21900907 0.80 CTSK (0.44) KMT2AMEN1SLC6A9ACHECTSL
SCHEMBL3024605 0.80 NAMPT (0.50) KMT2AMEN1
SCHEMBL27717381 0.79 SLC6A9 (0.48) KMT2AMEN1SLC6A9ACHECCR5
SCHEMBL15669852 0.78 SMN1; SMN2 (0.47) KMT2AMEN1SLC6A9L3MBTL1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210002251-A1 Bruton's Tyrosine Kinase Inhibitors PFIZER INC. (US) 2021-01-07 — — US disclosed
US-10815213-B2 Bruton's tyrosine kinase inhibitors PFIZER INC. (US) 2020-10-27 — — US disclosed
US-20190202798-A1 Bruton's Tyrosine Kinase Inhibitors PFIZER INC. (US) 2019-07-04 — — US disclosed
US-10266513-B2 Bruton's tyrosine kinase inhibitors PFIZER INC. (US) 2019-04-23 — — US disclosed
US-20170283393-A1 Bruton's Tyrosine Kinase Inhibitors PFIZER INC. (US) 2017-10-05 — — US disclosed
EP-2914586-B1 BRUTON'S TYROSINE KINASE INHIBITORS PFIZER (US) 2017-04-05 — — EP disclosed
US-20150291554-A1 Bruton's Tyrosine Kinase Inhibitors PFIZER (US) 2015-10-15 — — US disclosed
US-9012443-B2 Bicyclic aryl and heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-04-21 — — US disclosed
US-9012443-B2 Bicyclic aryl and heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-04-21 — — US disclosed
US-9012443-B2 Bicyclic aryl and heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-04-21 — — US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 — — US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 — — US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 — — US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 — — US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 — — US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 — — US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 — — US disclosed
WO-2010079443-A1 SULFONAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-07-15 — — WO disclosed
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases GALAPAGOS NV (BE) 2009-05-28 — — US disclosed
WO-2008055959-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266513-B2 Bruton's tyrosine kinase inhibitors BTK, LCK, LYN KMT2A 1448/4885MEN1 3787/4885KDM4D 1916/4885
US-20150291554-A1 Bruton's Tyrosine Kinase Inhibitors BTK, LCK, LYN KMT2A 1497/4885MEN1 3814/4885KDM4D 2350/4885
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 KMT2A 3314/4885MEN1 4141/4885KDM4D 3695/4885
US-10815213-B2 Bruton's tyrosine kinase inhibitors BTK, LCK, LYN KMT2A 1780/4885MEN1 3713/4885KDM4D 3027/4885
US-20210002251-A1 Bruton's Tyrosine Kinase Inhibitors BTK, LCK, LYN KMT2A 1780/4885MEN1 3713/4885KDM4D 3027/4885
US-20170283393-A1 Bruton's Tyrosine Kinase Inhibitors BTK, LCK, LYN KMT2A 1448/4885MEN1 3787/4885KDM4D 1916/4885
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases PDE4A, PDE7B, PDE4B KMT2A 3190/4885MEN1 4013/4885KDM4D 2254/4885
US-20190202798-A1 Bruton's Tyrosine Kinase Inhibitors BTK, LCK, SYK KMT2A 1643/4885MEN1 3731/4885KDM4D 2971/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 KMT2A 3314/4885MEN1 4141/4885KDM4D 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.